Investor Overview

NYSE: RNN
$1.87 - 0.11 (5.551%)
Data as of 10/19/17 at 1:47 PM ET
Minimum 20 minute delay
High 1.97
Low 1.87
Volume 443,305

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and SupinoxinTM (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.



©2017 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy